Show Notes
Excess mortality in England post Covid-19 pandemic: implications for secondary preventionUploaded 04-01-24https://www.sciencedirect.com/science/article/pii/S2666776223002211?via%3DihubMany countries, including the UK, have continued to experience an apparent excess of deaths long after the peaks associated with the COVID-19 pandemic in 2020 and 2021. Numbers of excess deaths estimated in this period are considerable. The UK Office for National Statistics (ONS) has calculated that there were 7.2% or 44,255 more deaths registered in the UK in 2022 OECD, UKhttps://stats.oecd.org/index.aspx?queryid=104676Excess deaths in 2022, 52,514 (9.26%)This persisted into 2023 with 8.6% or 28,024 more deaths registered in the first six months of the year than expected.OECD, UK, weeks 1 – 44, 2023Excess deaths, 49,389 (9.44%)The causes of these excess deaths are likely to be multiple and could include the direct effects of Covid-19 infection,acute pressures on NHS acute services resulting in poorer outcomes from episodes of acute illness,and disruption to chronic disease detection and management.Further analysis by cause and by age- and sex-group may help quantify the relative contributions of these causes.Office for Health Improvement and Disparities3rd June 2022 to 30th June 2023Excess deaths for all causes were relatively greatest for 50–64 year olds (15% higher than expected)11% higher for 25–49 and under 25 year olds,and about 9% higher for over 65sSeveral causes3rd June 2022–30th June 2023All cardiovascular diseases, 12%Heart failure, 20%Ischaemic heart disease, 15Liver diseases, 19%Acute respiratory infections, 14%Diabetes, 13% For middle-aged adults (50–64)Cardiovascular diseases, 33% higher than expectedIschaemic heart disease, 44%Cerebrovascular disease, 40%Heart failure 39% higherDeaths involving acute respiratory infections, 43% higherDiabetes, deaths were 35% higherThe pattern now is one of persisting excess deaths which are most prominent in relative terms in middle-aged and younger adultsTimely and granular analyses are needed to describe such trends and so to inform prevention and disease management efforts. JP-S is Partner at Lane Clark and Peacock LLP, Chair of the Royal Society for Public Health and reports personal fees from Novo Nordisk and Pfizer Ltd outside of this submitted work. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Dr. John Campbell
Well, this talk was sceduled for about 45 minutes, but ended up at nearly two hours. Link to original video: https://www.youtube.com/watch?v=mkRWsK6U6GA Learn more about your ad choices. Visit megaphone.fm/adchoices
I think a lot of this reaction is just sheer relief that at last someone is officially talking about this problem, affecting so many bereaved families.Uploaded 21-10-23If you live in the UK, you can contact your MP using this link, https://www.parliament.uk/get-involved/contact-an-mp-or-lord/contact-your-mp/Watch the debate live, https://www.parliamentlive.tv/Event/Index/00961342-e42c-431c-b26b-fda858dba69b Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Professor Angus Dalgleish, mRNA Vaccines Must Be Banned Once and For All
High infection rates in UK, going down in USUploaded 19-10-21https://www.telegraph.co.uk/news/2021/10/19/people-must-cautious-day-to-day-interactions-covid-cases-climb/Lower functional immunity in our population than most other Western European countriesEarly vaccine roll outAstraZeneca protects slightly less well than Pfizer against infection and transmission, particularly delta variantSlightly lower overall vaccination coverage, particularly vaccinating teenagersFewer social restrictionsHigh rates of testingUK, ONS https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsightsTwo vaccine doses give similar protection as previous infection Two doses of either Pfizer-BioNTech or Oxford-AstraZenecaProvided a similar level of protection as having had a previous natural infection of coronavirusDuring delta variant timesVaccination reduced the risk of testing positive, both when the alpha variant was dominant in the UK (1 December 2020 to 16 May 2021) and when the delta variant was dominant (17 May to 14 August 2021)Two doses of Pfizer-BioNTechReduced the risk of testing positive by 73% in the delta periodTwo doses of Oxford-AstraZenecaReduced the risk of testing positive by 62% in the delta periodTwo vaccination doses, more effective than one at preventing symptomatic infection in both periods. Three weeks after vaccinationTwo doses always more protective than one(75% v 58%)Inconsistent with covid symptom studyhttps://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covidTwo doses of the Pfizer87% protection against infectionTwo doses of the AstraZeneca71% protection against infectionNatural infection aloneOnly gave 65% protection against catching it againIsraeli data consistent with ONS but inconsistent with covid symptom studyProtection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdfVaccination was highly effective Estimated efficacy for documented infection of 92·8% Hospitalization 94·2% Severe illness 94·4% Death 93·7% Protection from prior SARS-CoV-2 infectionEstimated efficacy for documented infection of 94·8% Hospitalization 94·1% Severe illness 96·4%All deaths registered in the week to 8 October COVID-19 deaths fall in England, Northern Ireland and ScotlandUp in WalesTotal UK deaths in the week, 12,49014.7% above the average in 2015 to 2019820 involved the coronavirus (COVID-19)154 fewer than the previous weekDeaths involving COVID-19, 1 in 15 deaths (6.6%).UK total deaths include non-residents.1 million people in UK countries had COVID-19 in the latest week1.63% in England (1 in 60 people)One in 70 people the week before2.18% in Wales (1 in 45 people)One in 55 people the week before 0.82% in Northern Ireland (1 in 120 people)One in 130 people the week before 1.26% in Scotland (1 in 80 people)One in 60 people the week beforeGreg and PeterHello John, Just to let you know that one of my posts referring to your video on aspiration has been pulled from LinkedIn. This is the first time that one of my posts has been pulled and I have put out some pretty controversial posts on other subjects.Feedback from vaccine manufacturers Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
John talks with Professor Robert Clancy on the difficulties facing health care and health professionals in Australia and around the world.